Cargando…

P1080: COMPARISON OF NIVOLUMAB 40 MG EFFICACY VERSUS 3 MG/KG IN PATIENTS WITH RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA

Detalles Bibliográficos
Autores principales:	Fedorova, L., Lepik, K., Mikhailova, N., Kondakova, E., Komarova, Y., Popova, M., Kotselyabina, P., Borzenkova, E., Baykov, V., Moiseev, I., Kulagin, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430497/ http://dx.doi.org/10.1097/01.HS9.0000847188.87255.f7

Ejemplares similares

P062: The efficacy and safety of nivolumab 40 mg therapy versus 3 mg/kg in patients with relapsed and refractory classic Hodgkin lymphoma
por: Fedorova, Liudmila, et al.
Publicado: (2022)

P060: Prognosis of patients with relapsed and refractory classic Hodgkin lymphoma after nivolumab discontinuation and efficacy of nivolumab retreatment
por: Fedorova, Liudmila, et al.
Publicado: (2022)

A Phase 2 Study of Nivolumab Using a Fixed Dose of 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkin Lymphoma
por: Lepik, Kirill V., et al.
Publicado: (2020)

Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma
por: Fedorova, Liudmila V., et al.
Publicado: (2021)

A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure
por: Lepik, Kirill V., et al.
Publicado: (2020)

Immunosuppressive Microenvironment and Efficacy of PD-1 Inhibitors in Relapsed/Refractory Classic Hodgkin Lymphoma: Checkpoint Molecules Landscape and Macrophage Populations
por: Gusak, Artem, et al.
Publicado: (2021)

P1179: PROGNOSIS OF PATIENTS WITH AGGRESSIVE REFRACTORY B-NHL TREATED WITH GLOFITAMAB IN REAL CLINICAL PRACTICE
por: Fedorova, Liudmila, et al.
Publicado: (2023)

PB2308: NIVOLUMAB-BASED THERAPY OF RELAPSED OR REFRACTORY PRIMARY LARGE B-CELL LYMPHOMA OF IMMUNE-PRIVILEGED SITES AND DLBCL WITH SECONDARY CNS INVOLVEMENT
por: Gavrilenko, Andrey, et al.
Publicado: (2023)

Comparison of the anesthetic effects between 5 mg/kg of alfaxalone and 10 mg/kg of propofol administered intravenously in cats
por: TAMURA, Jun, et al.
Publicado: (2021)

Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors
por: Zhao, X., et al.
Publicado: (2017)

Benefit‐risk assessment of nivolumab 240 mg flat dose relative to 3 mg/kg Q2W regimen in Japanese patients with advanced cancers
por: Bei, Di, et al.
Publicado: (2020)

A Multicentre Randomized Controlled Trial of the Efficacy and Safety of Single-Dose Praziquantel at 40 mg/kg vs. 60 mg/kg for Treating Intestinal Schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil
por: Olliaro, Piero L., et al.
Publicado: (2011)

Comparison of the initial and residual speed of Ixodes scapularis kill on dogs treated with a single dose of Bravecto(®) Chew (25 mg/kg fluralaner) or Simparica TRIO(®) (1.2 mg/kg sarolaner, 24 µg/kg moxidectin, 5 mg/kg pyrantel)
por: Reif, Kathryn E., et al.
Publicado: (2023)

Modified electroconvulsive therapy in a resource-challenged setting: Comparison of two doses (0.5 mg/kg and 1 mg/kg) of suxamethonium chloride
por: Aaron, Olurotimi I., et al.
Publicado: (2020)

Efficacy and safety of praziquantel 40 mg/kg in preschool-aged and school-aged children: a meta-analysis
por: Zwang, Julien, et al.
Publicado: (2017)

Adequate exposure of 50 mg dolutegravir in children weighing 20 to 40 kg outside of sub-Sahara Africa
por: Waalewijn, Hylke, et al.
Publicado: (2022)

P738: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THERAPY-RELATED MYELODYSPLASTIC SYNDROME: A RETROSPECTIVE COHORT MATCHED STUDY
por: Kotselyabina, Polina, et al.
Publicado: (2023)

What is the easier and more reliable dose calculation for iv Phenytoin in children at risk of developing convulsive status epilepticus, 18 mg/kg or 20 mg/kg?
por: Prasad, Manish, et al.
Publicado: (2013)

Randomized Single-Blinded Non-inferiority Trial Of 7 mg/kg Pentamidine Isethionate Versus 4 mg/kg Pentamidine Isethionate for Cutaneous Leishmaniaisis in Suriname
por: Hu, Ricardo V. P. F., et al.
Publicado: (2015)

Analyses of Nivolumab Exposure and Clinical Safety Between 3-mg/kg Dosing and 240-mg Flat Dosing in Asian Patients with Advanced Renal Cell Carcinoma in the Real-World Clinical Setting
por: Kato, Renpei, et al.
Publicado: (2020)

Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
por: Ascierto, Paolo Antonio, et al.
Publicado: (2020)

P085: Epidemiology and results of the first line therapy of HIV-related Hodgkin Lymphoma: Russian retrospective multicenter study
por: Chekalov, Andrey, et al.
Publicado: (2022)

Correction: Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
Publicado: (2020)

Residual paralysis caused by 50 mg rocuronium after reversal with 4 mg/kg sugammadex: a case report
por: Uzawa, Kohji, et al.
Publicado: (2021)

Pharmacokinetics of acetaminophen after a single Oral administration of 20 or 40 mg/kg to 7–9 Day-old foals
por: Gold, Jenifer R., et al.
Publicado: (2023)

Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire
por: Tarhini, Ahmad, et al.
Publicado: (2018)

Comparing the frequency of isotretinoin-induced hair loss at <0.5-mg/kg/d versus ≥0.5-mg/kg/d dosing in acne patients: A systematic review
por: Lytvyn, Yuliya, et al.
Publicado: (2022)

Efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg
por: Grimaldi, Antonio M, et al.
Publicado: (2014)

Cardiovascular effect of dental anesthesia with articaine (40 mg with epinefrine 0,5 mg % and 40 mg with epinefrine 1 mg%) versus mepivacaine (30mg and 20 mg with epinefrine 1 mg%) in medically compromised cardiac patients: A cross-over, randomized, single blinded study
por: Torres-Lagares, Daniel, et al.
Publicado: (2012)

Is the rapid sequence induction possible with 0.6 mg/kg rocuronium in pediatric patient?
por: Lee, Sang Kyu, et al.
Publicado: (2010)

Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg(−1) rifampicin
por: te Brake, Lindsey H.M., et al.
Publicado: (2021)

Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia
por: Tamiru, Aschalew, et al.
Publicado: (2021)

Vancomycin efficiency and safety of a dosage of 40–60 mg/kg/d and corresponding trough concentrations in children with Gram-positive bacterial sepsis
por: Peng, Lengyue, et al.
Publicado: (2023)

P1077: HODGKIN LYMPHOMA IN PATIENTS WITH HIV: NATIONAL RETROSPECTIVE MULTICENTER STUDY
por: Chekalov, A., et al.
Publicado: (2022)

The abscopal effect: efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg
por: Grimaldi, Antonio M, et al.
Publicado: (2013)

Effects of 3 mg/kg Body Mass of Caffeine on the Performance of Jiu-Jitsu Elite Athletes
por: Merino-Fernández, María, et al.
Publicado: (2022)

To study the effect of high dose Atorvastatin 40 mg versus 80 mg in patients with dyslipidemia
por: Agrawal, Deepak, et al.
Publicado: (2018)

FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma
por: Kasamon, Yvette L., et al.
Publicado: (2017)

Nivolumab for Methotrexate-associated Classic Hodgkin's Lymphoma in a Rheumatoid Arthritis Patient
por: Tanaka, Keisuke, et al.
Publicado: (2019)

Effect of 3 and 6 mg/kg of caffeine on fat oxidation during exercise in healthy active females
por: Varillas-Delgado, David, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ne26dq8b2ftskb9fr392vnk5gj